Immunocore Holdings Plc Sponsored ADR IMCR 深 滬
等待開盤 10-23 09:30:00 美东时间
32.51
-1.060
-3.16%
華盛通- 最 高33.77
- 今 開33.39
- 成交量 34.51万股
- 最 低 31.52
- 昨 收 33.57
- 總市值 16.38亿
- 52周最高 39.3295
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 23.15
- 委 比 -14.63%
- 總股本 5038.71万
- 歷史最高 76.98
- 量 比 1.44
- 振 幅 6.70%
- 歷史最低 18.43
- 每 手 1
- 風險率 13.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
今天 10:06
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
今天 01:36
Immuron Q1 FY26 YoY growth
<p>Immunon Limited has reported ongoing sales growth for Travelan®, an over-the-counter immune supplement, with Q1 global sales reaching AUD$2.0 million, a 34% increase year-over-year. Australian sales led the growth at AUD$1.6 million, up 52%, driven by digital marketing, store expansion, and increased travel. US sales also rose 44% to AUD$0.4 million, boosted by improved Amazon presence and social media efforts. Canadian sales dropped 92% to AU...
10-13 10:00
Immuron Submits IMM-529 IND to FDA
Immuron Limited has submitted an IND application to the FDA for IMM-529, targeting Clostridioides difficile infection (CDI) and recurrent CDI. The company plans a Phase 2 clinical trial in 2026. IMM-529, an orally administered therapeutic, targets C. diff spores, toxins, and surface proteins. Preclinical results show promise in preventing and treating CDI. The drug addresses a critical need for new therapeutics to combat antibiotic-resistant C. d...
10-08 10:00
Guggenheim Assumes Immunocore Holdings at Neutral
Guggenheim analyst Paul Jeng assumes Immunocore Holdings (NASDAQ:IMCR) with a Neutral rating.
09-18 21:26
Immunocore to present at upcoming investor conferences
Immunocore Holdings plc (Nasdaq: IMCR) announced that its management will participate in several upcoming investor conferences in September 2025, including the Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, Baird 2025 Global Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. Presentations will be available via webcast and replay on Immunocore's website. The company s...
09-04 11:00
Immuron partners with InvestorHub
Immunot Limited has partnered with InvestorHub to launch an interactive investor hub, enhancing communication with shareholders and investors. The platform will feature regular updates, including videos, educational materials, and research. CEO Steven Lydeamore highlighted upcoming milestones: FDA submission and approval of IMM-529 IND and clinical trial results for Travelan®. The company focuses on developing orally administered antibodies for i...
08-27 02:29
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Immunocore reports second quarter financial results and provides a business update
Immunocore Holdings plc reported Q2 2025 net revenues of $98.0 million for KIMMTRAK, a 30% year-over-year increase. The company is advancing multiple clinical trials, including TEBE-AM (expected to complete enrollment in 1H 2026) and PRISM-MEL-301 (dose selection expected in 2H 2025). They also presented IMC-I109V HBV data at the 2025 AASLD Liver Meeting. Cash, cash equivalents, and marketable securities totaled $883 million as of June 30, 2025. ...
08-07 11:00
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
Immunocore Holdings plc (Nasdaq: IMCR), a biotech company specializing in immunomodulating medicines for cancer, infectious, and autoimmune diseases, announced it will release its Q2 financial results before US markets open on August 7, 2025. A live teleconference and webcast to discuss the results will follow at 8:00 a.m. EDT (1:00 p.m. BST). Immunocore’s ImmTAX platform focuses on TCR bispecific immunotherapies, with KIMMTRAK approved for treat...
07-31 06:00
